Toggle light / dark theme

An AAV variant selected through NHP screens robustly transduces the brain and drives secreted protein expression in NHPs and mice

Tecedor et al. used directed evolution to engineer AAVs with enhanced ependymal and brain delivery after injection into the cerebrospinal fluid. I think it would be interesting to try lumbar puncture delivery of these AAVs as well to see if they maintain decent biodistribution. (See my other post about Hinderer et al.’s paper: https://doi.org/10.1016/j.omtm.2020.04.012).


AAV capsid variants enriched for transduction of ventricular lining cells and brain parenchyma reduce the dose required for gene therapy to the CNS.

Specific cognitive abilities are highly heritable independent of general intelligence

A massive new meta-analysis reveals that individual cognitive abilities, like reading and math, rely on inherited DNA just as much as overall intelligence, suggesting people possess heavily customized genetic cognitive profiles independent of general smarts.

These tiny genetic fragments may be critical for telling a brain when to rest

The altered presence of tiny fragments of neuronal genes, called microexons, causes hyperarousal in zebrafish. This is the main conclusion of an international study led by Pompeu Fabra University (UPF) and the Center for Genomic Regulation (CRG). An abnormal pattern of neural microexon presence leads to a hyperarousal state characterized by heightened neural activity and insomnia, commonly associated with stress but also with neurodevelopmental disorders.

Arousal regulation is highly conserved in evolution. Therefore, this finding could help researchers understand the mechanism underlying some human neurodevelopmental disorders, such as autism and schizophrenia, conditions associated with microexon mutations.

To survive, animals need to be ready to react to external and internal stimuli. This activation of the central nervous system, arousal, is highly conserved throughout the animal kingdom.

Gene therapy shows promise in ARC syndrome, a deadly childhood liver disease

A new gene therapy has been used to successfully treat a deadly childhood liver disease in mice that model the disease, according to researchers at UCL and Great Ormond Street Hospital. Arthrogryposis, renal dysfunction and cholestasis (ARC) syndrome is a lethal genetic disorder usually caused by a lack of the VPS33B protein, with children diagnosed with the condition rarely living beyond their first year of life.

Now, in a study published in Nature Communications, the UCL-GOSH team found that by injecting a healthy version of the gene into the body, they can treat the condition in mice lacking VPS33B. Crucially, the final version of the treatment, which specifically targeted the liver cells, caused no harm. In the earlier versions, the genes became abnormally activated and caused cancerous cells to grow and expand in some cases.

While more tests must be done before the treatment can be tested in humans, the researchers’ breakthrough offers hope to babies with this devastating disorder and their families. In the UK, as many as six pregnancies per year might be affected by ARC syndrome. Furthermore, the findings may promote improved understanding of why some treatments may cause cancer.

The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation

Nelson et al. present a detailed biomolecular study of how the APOE-R136S mutation protects against Alzheimer’s disease (AD) in mice and in patient-derived cells. Lots of data on glial contributions and transcriptomic changes. I see this as an excellent target for gene therapies aiming to combat AD. So do the folks at Lexeo Therapeutics (an exciting company you should check out!)


Nelson et al. report that the APOE-R136S mutation protects against APOE4-promoted Alzheimer’s disease pathologies, including phosphorylated Tau accumulation, neuroinflammation and neurodegeneration, in mouse and human neuron models.

FOXO3: The Longevity Switch Inside Our Cells — Decoding the Master Regulator of Aging, Stress, and Disease

Aging is a universal biological process, yet the reasons why some individuals live significantly longer and healthier lives have long puzzled scientists. Among the genes linked to exceptional longevity, FOXO3 consistently stands out as one of the most influential “master controllers” of cellular resilience. This single transcription factor integrates signals from stress, metabolism, DNA repair, and stem cell biology, orchestrating a vast genetic program that determines how cells survive, adapt, or age [1].

In recent years, interest in FOXO3 has surged across aging research, regenerative medicine, oncology, and precision therapeutics. Variants of the FOXO3 gene are strongly associated with centenarian populations worldwide, while disruptions in its regulatory network contribute to multiple disorders, including cancer, neurodegeneration, metabolic decline, and tissue degeneration. With advances in computational biology and pathway analysis, it is now possible to map FOXO3’s complex signaling network and uncover new therapeutic strategies.

This blog post explores FOXO3’s multifaceted biological roles, its influence on disease, and what our curated data from TRANSFAC®, TRANSPATH®, and HumanPSD™ reveals about the FOXO3 regulatory network. The goal is to provide a scientifically rich yet accessible overview that sparks curiosity among researchers studying aging, longevity, and systems-level biology.

/* */